Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-224-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.60 million
Profitability
Miscellaneous
Employees75
OptionableOptionable
Organovo (NASDAQ:ONVO) Frequently Asked Questions
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo's earnings last quarter?
Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings results on Thursday, February, 7th. The medical research company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.01. The medical research company earned $0.78 million during the quarter, compared to analysts' expectations of $0.87 million. Organovo had a negative return on equity of 67.55% and a negative net margin of 770.79%. View Organovo's Earnings History.
When is Organovo's next earnings date?
What price target have analysts set for ONVO?
2 Wall Street analysts have issued 1 year target prices for Organovo's stock. Their predictions range from $1.75 to $2.50. On average, they anticipate Organovo's share price to reach $2.1250 in the next twelve months. This suggests a possible upside of 98.6% from the stock's current price. View Analyst Price Targets for Organovo.
What is the consensus analysts' recommendation for Organovo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organovo.
Has Organovo been receiving favorable news coverage?
Media stories about ONVO stock have trended neutral this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Organovo earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include PDL BioPharma (PDLI), Scholar Rock (SRRK), DBV TECHNOLOGIE/S (DBVT), Adaptimmune Therapeutics (ADAP), Replimune Group (REPL), Translate Bio (TBIO), Nightstar Therapeutics (NITE), Mesoblast (MESO), Agenus (AGEN), Avrobio (AVRO), CASI Pharmaceuticals (CASI), MeiraGTx (MGTX), Cellular Biomedicine Group (CBMG), Voyager Therapeutics (VYGR) and Gamida Cell (GMDA).
Who are Organovo's key executives?
Organovo's management team includes the folowing people:
- Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
- Mr. Craig Kussman, Chief Financial Officer (Age 60)
- Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
- Mr. Paul Gallant, Gen. Mang. (Age 54)
- Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
Who are Organovo's major shareholders?
Organovo's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.13%), Geode Capital Management LLC (1.10%), Bank of New York Mellon Corp (0.38%), D. E. Shaw & Co. Inc. (0.33%), Lehman & Derafelo Financial Resources LLC (0.17%) and Rhumbline Advisers (0.12%). View Institutional Ownership Trends for Organovo.
Which institutional investors are buying Organovo stock?
ONVO stock was purchased by a variety of institutional investors in the last quarter, including Lehman & Derafelo Financial Resources LLC, Bank of New York Mellon Corp, D. E. Shaw & Co. Inc., Geode Capital Management LLC, Rhumbline Advisers, Albion Financial Group UT, SG Americas Securities LLC and BlackRock Inc.. View Insider Buying and Selling for Organovo.
How do I buy shares of Organovo?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Organovo's stock price today?
One share of ONVO stock can currently be purchased for approximately $1.07.
How big of a company is Organovo?
Organovo has a market capitalization of $127.86 million and generates $4.60 million in revenue each year. The medical research company earns $-34,800,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Organovo employs 75 workers across the globe.
What is Organovo's official website?
How can I contact Organovo?
Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]
MarketBeat Community Rating for Organovo (NASDAQ ONVO)
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
